pemetrexed

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Breast Cancer

Conditions

Breast Cancer

Trial Timeline

May 1, 2003 → Jun 1, 2005

NCT ID

NCT00065533

About pemetrexed

pemetrexed is a phase 2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00065533. Target conditions include Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Breast Cancer were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Abemaciclib + Fulvestrant + Standard ChemotherapyEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00035061	Phase 2	Completed	—	—	Urologic Neoplasms
NCT03955042	Phase 1	Completed	Sep 6, 2019	Jan 18, 2023	Chordoma
NCT01473563	Phase 2	Completed	Dec 1, 2011	Sep 1, 2013	Nonsquamous Non-Small Cell Neoplasm of Lung
NCT00916630	Phase 1	Completed	Jan 1, 2009	Sep 1, 2015	Central Nervous System Lymphoma
NCT00732303	Phase 2	Terminated	Jan 1, 2009	Dec 1, 2010	Non-Small Cell Lung Cancer
NCT00864513	Phase 2	Terminated	Oct 1, 2007	Jul 1, 2009	Pancreas Cancer
NCT00520936	Phase 2	Completed	Sep 1, 2007	Feb 1, 2010	Osteosarcoma
NCT00523419	Phase 2	Completed	Sep 1, 2007	Jun 1, 2010	Osteosarcoma
NCT00540241	Pre-clinical	Completed	Sep 1, 2007	Mar 1, 2010	Non Small Cell Lung Cancer
NCT00497770	Pre-clinical	Completed	Feb 1, 2007	Mar 1, 2011	Lung Neoplasms
NCT00316225	Phase 2	Completed	Dec 1, 2006	Mar 1, 2009	Non-small Cell Lung Cancer
NCT00380718	Approved	Completed	Nov 1, 2006	Nov 1, 2009	Non-small Cell Lung Cancer
NCT00377520	Phase 2	Completed	Sep 1, 2006	Sep 1, 2008	Neoplasms
NCT00190918	Phase 2	Completed	Jul 1, 2006	Jul 1, 2007	Trophoblastic Neoplasms
NCT00330915	Phase 2	Completed	Jun 1, 2006	Jun 1, 2008	Rectal Neoplasms
NCT00109096	Phase 2	Completed	Jun 1, 2005	Mar 1, 2007	Ovarian Neoplasms
NCT00106002	Phase 2	Completed	Apr 1, 2005	Dec 1, 2007	Breast Cancer
NCT00216099	Phase 2	Completed	Feb 1, 2005	Mar 1, 2009	Prostate Cancer
NCT00190983	Phase 2	Completed	Feb 1, 2005	Oct 1, 2007	Cervical Intraepithelial Neoplasia
NCT00216216	Phase 2	Terminated	Jan 1, 2005	Oct 1, 2005	Small Cell Lung Cancer

Competing Products

20 competing products in Breast Cancer

See all competitors

Product	Company	Stage	Hype Score
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
Fulvestrant	Dr. Reddy's Laboratories	Pre-clinical	19
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35
Abemaciclib + Fulvestrant	Eli Lilly	Phase 2	27
VS-6766 + Abemaciclib + Fulvestrant	Eli Lilly	Phase 1/2	39
gemcitabine + vinorelbine	Eli Lilly	Phase 2	35
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
Azenosertib + Carboplatin + Pembrolizumab	Zentalis Pharmaceuticals	Phase 1/2	26
Abemaciclib	Eli Lilly	Pre-clinical	26
pemetrexed + cyclophosphamide + doxorubicin + docetaxel	Eli Lilly	Phase 2	35
arzoxifene	Eli Lilly	Approved	43
BBI-355 + Erlotinib + Futibatinib + BBI-825	Boundless Bio	Phase 1	23
BBI-940 + Fulvestrant	Boundless Bio	Phase 1	26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
pemetrexed + gemcitabine	Eli Lilly	Phase 2	35